| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 16 | 2026 | 53 | 4.590 |
Why?
|
| Clinical Trials as Topic | 8 | 2023 | 462 | 2.160 |
Why?
|
| Quality Assurance, Health Care | 6 | 2021 | 253 | 2.120 |
Why?
|
| Neoplasms | 15 | 2026 | 1377 | 2.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 13 | 2026 | 65 | 2.010 |
Why?
|
| Hodgkin Disease | 10 | 2019 | 54 | 1.630 |
Why?
|
| Radiosurgery | 3 | 2021 | 69 | 1.520 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2024 | 37 | 1.470 |
Why?
|
| Radiotherapy | 5 | 2026 | 66 | 1.280 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 274 | 1.150 |
Why?
|
| Radiotherapy, Conformal | 4 | 2023 | 19 | 1.080 |
Why?
|
| Radiation Injuries | 5 | 2019 | 67 | 1.060 |
Why?
|
| Clinical Protocols | 5 | 2018 | 138 | 1.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2022 | 466 | 0.960 |
Why?
|
| Kidney Neoplasms | 4 | 2026 | 173 | 0.950 |
Why?
|
| Influenza, Human | 3 | 2017 | 213 | 0.950 |
Why?
|
| Proton Therapy | 4 | 2026 | 12 | 0.920 |
Why?
|
| Radiation Tolerance | 4 | 2024 | 56 | 0.880 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 712 | 0.880 |
Why?
|
| Prostatic Neoplasms | 6 | 2018 | 502 | 0.860 |
Why?
|
| Pandemics | 3 | 2017 | 692 | 0.800 |
Why?
|
| Radiotherapy Dosage | 13 | 2026 | 88 | 0.760 |
Why?
|
| Insurance Carriers | 1 | 2021 | 7 | 0.690 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2018 | 37 | 0.680 |
Why?
|
| Heart | 2 | 2026 | 298 | 0.680 |
Why?
|
| Hematuria | 1 | 2021 | 23 | 0.670 |
Why?
|
| Humans | 74 | 2026 | 65837 | 0.670 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 20 | 0.660 |
Why?
|
| Disaster Planning | 3 | 2017 | 57 | 0.650 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 46 | 0.650 |
Why?
|
| Nephrectomy | 1 | 2021 | 93 | 0.650 |
Why?
|
| Civil Defense | 2 | 2017 | 16 | 0.640 |
Why?
|
| Developing Countries | 2 | 2017 | 87 | 0.620 |
Why?
|
| Child | 22 | 2026 | 4651 | 0.610 |
Why?
|
| International Cooperation | 3 | 2018 | 87 | 0.570 |
Why?
|
| Tissue Expansion Devices | 3 | 2017 | 17 | 0.570 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 16 | 0.570 |
Why?
|
| Palliative Care | 1 | 2021 | 251 | 0.560 |
Why?
|
| Lymphoma | 1 | 2019 | 101 | 0.550 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 175 | 0.540 |
Why?
|
| Mass Vaccination | 1 | 2017 | 8 | 0.530 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 309 | 0.510 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 1235 | 0.490 |
Why?
|
| Pharmacies | 1 | 2016 | 36 | 0.480 |
Why?
|
| Radiodermatitis | 2 | 2016 | 11 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 186 | 0.470 |
Why?
|
| Public Health | 1 | 2016 | 188 | 0.420 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1569 | 0.420 |
Why?
|
| Film Dosimetry | 1 | 2014 | 10 | 0.420 |
Why?
|
| Lung | 2 | 2021 | 969 | 0.420 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 142 | 0.420 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 322 | 0.410 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 12 | 0.410 |
Why?
|
| Diaphragm | 1 | 2014 | 25 | 0.410 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 264 | 0.410 |
Why?
|
| Tissue Expansion | 3 | 2020 | 24 | 0.390 |
Why?
|
| Wilms Tumor | 2 | 2026 | 5 | 0.380 |
Why?
|
| Androgens | 2 | 2010 | 67 | 0.360 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 25 | 0.350 |
Why?
|
| Neuropilin-2 | 2 | 2024 | 40 | 0.350 |
Why?
|
| Oximetry | 1 | 2012 | 53 | 0.350 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 1573 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 71 | 0.340 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 213 | 0.330 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 67 | 0.330 |
Why?
|
| Male | 31 | 2026 | 31406 | 0.310 |
Why?
|
| Whole-Body Irradiation | 3 | 2024 | 34 | 0.300 |
Why?
|
| Quality of Health Care | 1 | 2014 | 535 | 0.300 |
Why?
|
| Female | 32 | 2026 | 34423 | 0.300 |
Why?
|
| Adolescent | 12 | 2026 | 6367 | 0.290 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 5 | 0.290 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 367 | 0.290 |
Why?
|
| Anilides | 1 | 2008 | 18 | 0.290 |
Why?
|
| Integrins | 3 | 2016 | 109 | 0.280 |
Why?
|
| Nitriles | 1 | 2008 | 82 | 0.280 |
Why?
|
| United States | 10 | 2020 | 8189 | 0.280 |
Why?
|
| Organs at Risk | 2 | 2026 | 6 | 0.280 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2020 | 9 | 0.280 |
Why?
|
| Phantoms, Imaging | 3 | 2026 | 242 | 0.280 |
Why?
|
| Child, Preschool | 10 | 2026 | 2089 | 0.270 |
Why?
|
| Prognosis | 5 | 2022 | 1794 | 0.270 |
Why?
|
| Young Adult | 10 | 2021 | 4882 | 0.270 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 25 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2023 | 70 | 0.240 |
Why?
|
| Chemoradiotherapy | 4 | 2020 | 75 | 0.240 |
Why?
|
| Influenza Vaccines | 2 | 2017 | 100 | 0.230 |
Why?
|
| Terminology as Topic | 2 | 2017 | 145 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2026 | 1665 | 0.230 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 88 | 0.220 |
Why?
|
| Ammonia | 1 | 2024 | 17 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2016 | 86 | 0.210 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 134 | 0.210 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 34 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 264 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2024 | 165 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 645 | 0.200 |
Why?
|
| Adenoma | 1 | 2023 | 70 | 0.200 |
Why?
|
| Feces | 1 | 2023 | 122 | 0.190 |
Why?
|
| Colonoscopy | 1 | 2023 | 97 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 196 | 0.190 |
Why?
|
| Aged | 14 | 2023 | 15146 | 0.190 |
Why?
|
| Oxidative Stress | 1 | 2024 | 323 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 54 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2023 | 3339 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 234 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 2500 | 0.170 |
Why?
|
| Vincristine | 5 | 2022 | 26 | 0.170 |
Why?
|
| Sarcoma | 2 | 2018 | 36 | 0.170 |
Why?
|
| Medulloblastoma | 1 | 2021 | 13 | 0.170 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 553 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 5682 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2021 | 98 | 0.160 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 7 | 0.160 |
Why?
|
| Cisplatin | 6 | 2018 | 145 | 0.160 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2020 | 8 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 290 | 0.160 |
Why?
|
| Adult | 12 | 2021 | 17575 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2021 | 153 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 427 | 0.150 |
Why?
|
| Meningeal Neoplasms | 2 | 2015 | 63 | 0.150 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 17 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 63 | 0.150 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 233 | 0.150 |
Why?
|
| Doxorubicin | 6 | 2020 | 98 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 196 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2018 | 326 | 0.150 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 51 | 0.150 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 33 | 0.150 |
Why?
|
| Middle Aged | 13 | 2023 | 18498 | 0.150 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 245 | 0.140 |
Why?
|
| Mice | 9 | 2024 | 11185 | 0.140 |
Why?
|
| Infratentorial Neoplasms | 1 | 2018 | 4 | 0.140 |
Why?
|
| Radiometry | 1 | 2018 | 39 | 0.140 |
Why?
|
| Combined Modality Therapy | 7 | 2018 | 375 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2024 | 3170 | 0.140 |
Why?
|
| Brain Stem | 1 | 2018 | 30 | 0.140 |
Why?
|
| Oligopeptides | 1 | 2018 | 135 | 0.140 |
Why?
|
| Choice Behavior | 2 | 2016 | 86 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2017 | 36 | 0.130 |
Why?
|
| Cyclophosphamide | 5 | 2020 | 84 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2018 | 201 | 0.130 |
Why?
|
| Mammaplasty | 2 | 2016 | 47 | 0.130 |
Why?
|
| Skin | 3 | 2018 | 436 | 0.120 |
Why?
|
| Infant | 6 | 2026 | 1719 | 0.120 |
Why?
|
| Vaccination Coverage | 1 | 2016 | 9 | 0.120 |
Why?
|
| Transfection | 1 | 2018 | 700 | 0.120 |
Why?
|
| Cell Survival | 1 | 2018 | 588 | 0.120 |
Why?
|
| Beta Particles | 1 | 2016 | 2 | 0.120 |
Why?
|
| Immunization | 1 | 2016 | 135 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 741 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 875 | 0.120 |
Why?
|
| Information Management | 1 | 2015 | 12 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 603 | 0.120 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 46 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 87 | 0.120 |
Why?
|
| Mastectomy | 2 | 2014 | 56 | 0.120 |
Why?
|
| Etoposide | 4 | 2018 | 34 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 65 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2329 | 0.110 |
Why?
|
| Oxygen | 2 | 2016 | 323 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2013 | 287 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 711 | 0.110 |
Why?
|
| Pharmacists | 1 | 2016 | 131 | 0.110 |
Why?
|
| RNA Interference | 1 | 2018 | 647 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 1 | 0.110 |
Why?
|
| Learning | 1 | 2016 | 186 | 0.110 |
Why?
|
| Global Health | 1 | 2015 | 181 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 134 | 0.100 |
Why?
|
| Data Collection | 1 | 2015 | 384 | 0.100 |
Why?
|
| Osteolysis | 1 | 2014 | 19 | 0.100 |
Why?
|
| Animals | 9 | 2024 | 21493 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 49 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 29 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 2324 | 0.100 |
Why?
|
| Prednisone | 3 | 2020 | 83 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 162 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6955 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2790 | 0.100 |
Why?
|
| Integrin beta1 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 2 | 2004 | 15 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 117 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 377 | 0.090 |
Why?
|
| Monte Carlo Method | 2 | 2026 | 102 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 634 | 0.090 |
Why?
|
| Credentialing | 1 | 2012 | 16 | 0.090 |
Why?
|
| Thalidomide | 1 | 2012 | 33 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2008 | 51 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 84 | 0.080 |
Why?
|
| Bleomycin | 3 | 2018 | 35 | 0.080 |
Why?
|
| Medical Informatics | 1 | 2012 | 72 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1117 | 0.080 |
Why?
|
| Decision Making | 1 | 2015 | 430 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 210 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2020 | 5834 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 413 | 0.080 |
Why?
|
| Fluorouracil | 3 | 2017 | 68 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 59 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 961 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 809 | 0.070 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 142 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2012 | 102 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2022 | 274 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 182 | 0.070 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cytarabine | 3 | 2018 | 36 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1172 | 0.070 |
Why?
|
| Fibronectins | 1 | 2008 | 44 | 0.070 |
Why?
|
| Brain | 1 | 2017 | 1672 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 589 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 218 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 310 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 849 | 0.060 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 286 | 0.060 |
Why?
|
| Cetuximab | 2 | 2017 | 8 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1719 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 354 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 94 | 0.060 |
Why?
|
| Remission Induction | 3 | 2014 | 149 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1044 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2004 | 378 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2018 | 214 | 0.050 |
Why?
|
| Mice, Hairless | 2 | 2016 | 19 | 0.050 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 124 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 12 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 44 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 61 | 0.050 |
Why?
|
| Fibrosis | 2 | 2016 | 172 | 0.050 |
Why?
|
| Immunochemistry | 1 | 2023 | 9 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2018 | 1439 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 19 | 0.050 |
Why?
|
| RNA, Small Untranslated | 1 | 2023 | 19 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 665 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 1029 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 130 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 588 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 60 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 223 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 45 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 3777 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 166 | 0.040 |
Why?
|
| Massachusetts | 2 | 2018 | 2158 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2010 | 579 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 327 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 995 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 27 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 89 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2016 | 2168 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 20 | 0.040 |
Why?
|
| Neuropilins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2019 | 30 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 357 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 170 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1595 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 70 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 527 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 3 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 7 | 0.030 |
Why?
|
| Photons | 1 | 2018 | 23 | 0.030 |
Why?
|
| Texas | 1 | 2018 | 60 | 0.030 |
Why?
|
| Florida | 1 | 2018 | 46 | 0.030 |
Why?
|
| Uncertainty | 1 | 2018 | 40 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2018 | 13 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2012 | 75 | 0.030 |
Why?
|
| Mass Screening | 1 | 2023 | 700 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 75 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2018 | 48 | 0.030 |
Why?
|
| Extremities | 1 | 2018 | 63 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 39 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 77 | 0.030 |
Why?
|
| Leukemia | 1 | 2018 | 62 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 218 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 484 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 45 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 56 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2018 | 54 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 148 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 263 | 0.030 |
Why?
|
| Wound Healing | 1 | 2018 | 193 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2017 | 21 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 111 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 441 | 0.030 |
Why?
|
| Habits | 1 | 2016 | 21 | 0.030 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2739 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 2016 | 14 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 42 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 593 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 746 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 30 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 206 | 0.030 |
Why?
|
| Reward | 1 | 2016 | 89 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 23 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1229 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 108 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 102 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 135 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 113 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 806 | 0.030 |
Why?
|
| Concept Formation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 25 | 0.030 |
Why?
|
| Knowledge | 1 | 2015 | 33 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 102 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5476 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 127 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 61 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 114 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 67 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 664 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 187 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 41 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 899 | 0.030 |
Why?
|
| Software | 1 | 2017 | 401 | 0.030 |
Why?
|
| Postmenopause | 1 | 2015 | 241 | 0.030 |
Why?
|
| Breast | 1 | 2016 | 194 | 0.030 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 463 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 65 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2016 | 301 | 0.020 |
Why?
|
| Pain Management | 1 | 2015 | 174 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 30 | 0.020 |
Why?
|
| Health Services Research | 1 | 2014 | 265 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 241 | 0.020 |
Why?
|
| Razoxane | 1 | 2012 | 2 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 995 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 263 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 230 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 518 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 859 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 224 | 0.020 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2012 | 2 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 47 | 0.020 |
Why?
|
| Metribolone | 1 | 2011 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 12 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 149 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 74 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 935 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2012 | 74 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 296 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 1561 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 2002 | 140 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 420 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 114 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1267 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2010 | 21 | 0.020 |
Why?
|
| Carmustine | 1 | 2009 | 11 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1292 | 0.020 |
Why?
|
| Internationality | 1 | 2009 | 46 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 192 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 94 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 157 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 41 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 61 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 963 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2115 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2651 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 606 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1100 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 77 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 299 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 932 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 993 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 92 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2004 | 51 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 120 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 140 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 208 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 41 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2002 | 73 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 101 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 44 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 81 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 300 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 312 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 289 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 192 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1433 | 0.010 |
Why?
|